Security
Inovio Pharmaceuticals, Inc. Common Stock · INO
INONASDAQCommon stockCurrentCIK 1055726Updated Nov 4, 2026
Name history
INOVIO BIOMEDICAL CORP · through May 11, 2010GENETRONICS BIOMEDICAL CORP · through Apr 1, 2005GENETRONICS BIOMEDICAL LTD · through Aug 3, 2001
INO price & chart
Loading TradingView…
NASDAQ:INO on TradingView ↗About the company
INOVIO’s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO’s proprietary medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that enable the body’s cells to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body’s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
In the news
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO ↗
INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 ↗
INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit ↗
Seeking Alpha
Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages ↗
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript ↗
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP - Slideshow ↗
SEC disclosures
INOVIO PHARMACEUTICALS, INC. files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G/A - filed by Adage Capital Management, L.P. regarding INOVIO PHARMACEUTICALS, INC.
Show 5 more recent filings
SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding INOVIO PHARMACEUTICALS, INC.
SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding INOVIO PHARMACEUTICALS, INC.
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
Results of Operations and Financial Condition
Items 2.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 69,385,656Source | 107,059,674Source | 49,389,494Source | 68,240,504Source | 133,797,203Source | 49,777,142Source | 87,272,659Source | 129,114,165Source | 74,310,035Source | 113,197,206Source | 170,951,423Source | 348,533,302Source |
| Property, Plant and Equipment, NetUSD | 2,740,356Source | 4,091,562Source | 1,888,725Source | 3,089,293Source | 4,510,869Source | 2,210,759Source | 3,347,824Source | 5,015,067Source | 2,527,603Source | 3,659,818Source | 4,960,986Source | 7,727,997Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 10,513,371Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,129,861Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 36,567,420Source | 21,687,480Source | 31,526,164Source | 24,351,377Source | 34,392,404Source | 26,271,650Source | 39,915,447Source | 19,601,829Source | 44,273,319Source | 65,813,297Source | 14,310,862Source | 46,329,359Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 978,590Source | 1,862,739Source | — | 840,312Source | 1,773,665Source | — | 1,310,237Source | 2,551,082Source | 450Source | 1,199,056Source | — | 1,701,726Source |
| Assets, CurrentUSD | 55,180,314Source | 91,284,623Source | 39,913,249Source | 52,697,149Source | 117,561,045Source | 39,439,605Source | 71,894,449Source | 111,683,036Source | 61,123,346Source | 97,830,050Source | 153,113,100Source | 315,242,680Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,398,534Source | 4,617,116Source | 3,239,232Source | 4,307,377Source | 5,365,860Source | 1,758,348Source | 2,221,668Source | 3,517,081Source | 2,610,882Source | 2,517,465Source | 5,393,665Source | 50,130,481Source |
| Operating Lease, Right-of-Use AssetUSD | 6,956,780Source | 8,472,848Source | 5,670,451Source | 7,356,238Source | 8,819,399Source | 6,114,303Source | 7,741,757Source | 9,156,478Source | 6,542,923Source | 8,113,840Source | 9,491,735Source | 10,228,207Source |
| Other Assets, NoncurrentUSD | 2,012,476Source | 566,415Source | 1,917,069Source | 2,012,476Source | 585,915Source | 2,012,475Source | 1,979,654Source | 605,315Source | 2,012,475Source | 1,979,654Source | 605,315Source | 684,044Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 77,105,633Source | 33,519,364Source | 45,018,411Source | 39,709,599Source | 37,057,996Source | 43,709,260Source | 36,021,935Source | 34,672,202Source | 50,213,759Source | 44,693,411Source | 53,602,294Source | 126,170,546Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 53,572Source | 26,051Source | 82,342Source | 36,719Source | 25,962Source | 69,773Source | 36,674Source | 23,370Source | 68,997Source | 36,099Source | 22,792Source | 253,090Source |
| Additional Paid in CapitalUSD | 1,811,803,850Source | 1,784,975,303Source | 1,845,429,136Source | 1,802,589,299Source | 1,783,074,886Source | 1,841,482,163Source | 1,801,789,329Source | 1,748,529,814Source | 1,839,830,405Source | 1,799,362,625Source | 1,740,954,074Source | 1,710,656,191Source |
| Retained Earnings (Accumulated Deficit)USD | -1,818,930,043Source | -1,710,837,583Source | -1,840,860,419Source | -1,773,433,371Source | -1,685,672,105Source | -1,834,847,961Source | -1,749,913,959Source | -1,653,435,007Source | -1,815,165,163Source | -1,730,219,262Source | -1,622,965,136Source | -1,487,847,784Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -647,356Source | -623,461Source | -279,976Source | -661,742Source | -689,536Source | -636,093Source | -661,320Source | -676,214Source | -637,963Source | -675,667Source | -662,601Source | -698,741Source |
| Stockholders' Equity Attributable to ParentUSD | -7,719,977Source | 73,540,310Source | 4,371,083Source | 28,530,905Source | 96,739,207Source | 6,067,882Source | 51,250,724Source | 94,441,963Source | 24,096,276Source | 68,503,795Source | 117,349,129Source | 222,362,756Source |
| Liabilities and EquityUSD | 69,385,656Source | 107,059,674Source | 49,389,494Source | 68,240,504Source | 133,797,203Source | 49,777,142Source | 87,272,659Source | 129,114,165Source | 74,310,035Source | 113,197,206Source | 170,951,423Source | 348,533,302Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 69,823,896Source | 23,499,137Source | 39,915,059Source | 31,707,610Source | 26,399,768Source | 37,923,025Source | 27,326,880Source | 23,400,945Source | 43,668,555Source | 35,325,584Source | 42,570,228Source | 96,868,074Source |
| Operating Lease, Liability, CurrentUSD | 2,738,490Source | 2,425,112Source | 2,898,637Source | 2,656,239Source | 2,321,984Source | 2,908,820Source | 2,575,902Source | 2,155,540Source | 2,822,622Source | 2,497,360Source | 2,406,522Source | 2,803,973Source |
| Operating Lease, Liability, NoncurrentUSD | 7,281,737Source | 10,020,227Source | 5,103,352Source | 8,001,989Source | 10,658,228Source | 5,786,235Source | 8,695,055Source | 11,271,257Source | 6,545,204Source | 9,367,827Source | 11,032,066Source | 12,655,586Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 32,046Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 50,800,000Source | 84,800,000Source | 36,700,000Source | 47,500,000Source | 110,400,000Source | 37,700,000Source | 68,400,000Source | 105,600,000Source | 58,500,000Source | 94,100,000Source | 145,300,000Source | 253,000,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 32,000Source |
| Short-term InvestmentsUSD | 14,235,770Source | 63,117,288Source | 5,147,853Source | 23,198,083Source | 76,029,116Source | 11,409,607Source | 28,447,097Source | 86,013,044Source | 14,239,145Source | 28,300,232Source | 130,982,913Source | 206,669,397Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -279,818,065Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 698,744Source | 1,399,349Source | 3,755,788Source | 6,595,108Source | 11,072,486Source | 22,555,419Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | 111,181Source | — | -1,206,172Source | -9,332,988Source | 3,706,172Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | -32,046Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -21,591,316Source | -26,874,027Source | -88,629,430Source | -104,076,553Source | -124,365,551Source | -216,215,421Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,635,857Source | -51,753Source | 14,039,357Source | 104,071,039Source | 87,355,875Source | 109,585,856Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 59,373Source | 285,698Source | 487,832Source | 320,898Source | 969,153Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 953,790Source | 1,027,930Source | 53,050,095Source | 51,475,546Source | 4,995,099Source | 81,840,702Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -18,001,669Source | -25,897,850Source | -21,539,978Source | 51,502,435Source | -32,018,497Source | -24,814,419Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 36,567,420Source | 21,687,480Source | 31,526,164Source | 24,351,377Source | 26,271,650Source | 39,915,447Source | 44,273,319Source | 65,813,297Source | 14,310,862Source | 46,329,359Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 533,487Source | 1,066,975Source | 1,066,975Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 32,403Source | -3,920Source | -25,556Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 3,700,000Source | 6,400,000Source | 10,400,000Source | 22,200,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 0Source | 145,417Source | 496,494Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 50,800,000Source | 84,800,000Source | 36,700,000Source | 47,500,000Source | 37,700,000Source | 68,400,000Source | 58,500,000Source | 94,100,000Source | 145,300,000Source | 253,000,000Source |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| DepreciationUSD | — | — | — | — | — | — | 316,844Source | 371,367Source | 1,417,913Source | 1,752,147Source | 2,621,649Source | 3,656,713Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 205,259Source | 1,330,811Source | 94,221Source | 759,289Source | 79,077Source | 140,234Source | 1,114,781Source | 2,077,182Source | 5,850,626Source | -7,846,172Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -2,165,213Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 22,466Source | -317,997Source | -1,074,830Source |
| General and Administrative ExpenseUSD | — | — | 7,877,126Source | 8,613,895Source | 7,797,973Source | 8,563,112Source | 7,879,886Source | 9,024,970Source | 32,680,573Source | 36,996,338Source | 47,582,104Source | 90,185,285Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 10,513,371Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | — | — | — | — | — | 12,497,815Source | — |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 10,513,371Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,984,444Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -2,165,213Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 177,833Source | — | — |
| Investment Income, InterestUSD | — | — | 552,108Source | 1,106,758Source | 363,847Source | 610,638Source | 439,593Source | 808,077Source | 2,420,160Source | 4,766,993Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -45,496,672Source | -25,165,478Source | -6,012,458Source | -23,519,412Source | -19,682,798Source | -19,694,697Source | -84,945,901Source | -107,254,126Source | -135,117,352Source | -279,818,065Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Operating ExpensesUSD | — | — | 21,210,455Source | 27,347,479Source | 18,624,522Source | 23,084,519Source | 21,949,993Source | 25,115,872Source | 86,887,447Source | 112,616,678Source | 144,772,038Source | 277,835,788Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,938,236Source | -579,819Source | -1,714,620Source | -703,183Source | -285,490Source | -482Source | -2,641,813Source | -3,163,711Source | -4,711,596Source | -3,861,584Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,084,027Source | 1,102,149Source | 34,908,593Source | 36,033,473Source | 5,461,745Source | 82,955,311Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 823Source | 67,675Source | 0Source | 283,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | -632,000Source | -1,700,000Source | -720,000Source | -1,900,000Source | -3,900,000Source | -8,700,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 65,343Source | 65,343Source | 217,756Source | 832,010Source | 10,262,268Source |
| Operating Income (Loss)USD | — | — | -21,210,455Source | -27,347,479Source | -18,624,522Source | -23,084,519Source | -21,949,993Source | -25,050,529Source | -86,822,104Source | -112,398,922Source | -143,940,028Source | -267,573,520Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,938,236Source | -579,819Source | -1,714,620Source | -703,183Source | -285,490Source | -482Source | -2,641,813Source | -3,163,711Source | -4,711,596Source | -3,861,584Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -84,945,901Source | -107,254,126Source | -135,117,351Source | -277,652,052Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -45,496,672Source | -25,165,478Source | -6,012,458Source | -23,519,412Source | -19,682,798Source | -19,694,697Source | -84,945,901Source | -107,254,126Source | -135,117,352Source | -279,818,065Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.87Source | -0.89Source | -0.07Source | -0.61Source | -0.28Source | -0.51Source | -1.81Source | -3.95Source | -6.09Source | -1.17Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.87Source | -0.89Source | -0.07Source | -0.61Source | -0.28Source | -0.51Source | -1.81Source | -3.95Source | -6.09Source | -1.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 52,168,694Source | 28,140,497Source | 81,619,113Source | 38,830,053Source | 69,101,910Source | 38,613,653Source | 46,886,413Source | 27,160,863Source | 22,173,662Source | 238,622,188Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 52,168,694Source | 28,140,497Source | 81,619,113Source | 38,830,053Source | 69,101,910Source | 38,613,653Source | 46,886,413Source | 27,160,863Source | 22,173,662Source | 238,622,188Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 177,833Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | 0Source | 145,417Source | 496,494Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 7,877,126Source | 8,613,895Source | 7,797,973Source | 8,563,112Source | 7,879,886Source | 9,024,970Source | 32,680,573Source | 36,996,338Source | 47,582,104Source | 90,185,285Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 10,513,371Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -84,945,901Source | -107,254,126Source | -134,979,579Source | -277,440,803Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -2,165,213Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,222,789Source | 1,253,952Source |
| Interest Income, OperatingUSD | — | — | — | — | — | — | — | — | — | — | 8,133,290Source | 4,782,030Source |
| Investment Income, InterestUSD | — | — | 552,108Source | 1,106,758Source | 363,847Source | 610,638Source | 439,593Source | 808,077Source | 2,420,160Source | 4,766,993Source | — | — |
| Operating ExpensesUSD | — | — | 21,210,455Source | 27,347,479Source | 18,624,522Source | 23,084,519Source | 21,949,993Source | 25,115,872Source | 86,887,447Source | 112,616,678Source | 144,772,038Source | 277,835,788Source |
| Research and Development ExpenseUSD | — | — | 13,333,329Source | 18,733,584Source | 10,826,549Source | 14,521,407Source | 14,070,107Source | 16,090,902Source | 54,206,874Source | 75,620,340Source | 86,676,563Source | 187,650,503Source |
Offerings
Registration 333-297233
Filing attachments
d150457dex991.htm · 8-K · 2026-11-02
Exhibit 99.1 INOVIO Announces FDA Accelerated Approval of VOCERYQ ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make VOCERYQ available to or…
Read attachment ↗d150457dex992.htm · 8-K · 2026-11-02
FDA Accelerated Approval of VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Investor Call November 2, 2026 Exhibit 99.2 Agenda for VOCERYQ™ Approval Call Introduction Jacqueline Shea, PhD, President & Chief Executive Officer Prescribing Information and Label Details Michael Sumner, MBBS, MBA, Chief Medical Officer Commercial Launch Plans Steve Egge, MBA, Chief Commercial Officer VOCERYQ™ and Platform Potential Jacqueline Shea, PhD, President & Chief Executive Officer Th…
Read attachment ↗ino-63026x8kex991.htm · 8-K · 2026-08-12
EX-99.1 2 ino-63026x8kex991.htm EX-99.1 Document Exhibit 99.1 INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights • U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 • Commercial preparations advancing in anticipation of potential product launch for INO-3107 •…
Read attachment ↗d253972dex41.htm · 8-K · 2026-07-31
EX-4.1 3 d253972dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. Warrant Shares: Date of Issuance: July 31, 2026 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at…
Read attachment ↗d253972dex42.htm · 8-K · 2026-07-31
EX-4.2 4 d253972dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: July 31, 2026 ────────────────────────────────────────────────────── THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [___] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the I…
Read attachment ↗d253972dex991.htm · 8-K · 2026-07-31
EX-99.1 6 d253972dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA - July 29, 2026 /PRNewswire/ - INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of …
Read attachment ↗